Insider · CIK 0001491874

Parker Geoffrey M.

CIK 0001491874 Name as filed on the most recent filing

Filed as Parker Geoffrey M. (53)

88 transaction lines · from 53 filings · filed 2011-05-11 to 2026-02-04 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

88 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-25 05:24 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2026-02-02 S, Open-market sale Allogene Therapeutics, Inc.ALLO 42,242, disposed Open Form 4 filing 0001737287-26-000007
2025-11-12 P, Open-market purchase Perrigo Co plcPRGO 106,350, acquired Open Form 4 filing 0001491874-25-000007
2025-10-21 S, Open-market sale Allogene Therapeutics, Inc.ALLO 46,169, disposed Open Form 4 filing 0001737287-25-000091
2025-08-18 P, Open-market purchase Perrigo Co plcPRGO 100,497, acquired Open Form 4 filing 0001585364-25-000130
2025-08-18 P, Open-market purchase Perrigo Co plcPRGO 100,497, acquired Open Form 4 filing 0001585364-25-000128
2025-05-12 P, Open-market purchase Perrigo Co plcPRGO 94,850, acquired Open Form 4 filing 0001585364-25-000058
2025-02-03 S, Open-market sale Allogene Therapeutics, Inc.ALLO 7,545, disposed Open Form 4 filing 0001737287-25-000019
2024-01-30 P, Open-market purchase Allogene Therapeutics, Inc.ALLO 683, acquired Open Form 4 filing 0001593968-24-000449
2023-07-27 P, Open-market purchase Better Therapeutics, Inc.BTTX 500,000, acquired Open Form 4 filing 0000950170-23-035679
2023-06-13 P, Open-market purchase Perrigo Co plcPRGO 330,637, acquired Open Form 4 filing 0001585364-23-000106
2023-04-10 P, Open-market purchase Better Therapeutics, Inc.BTTX 250,000, acquired Open Form 4 filing 0000899243-23-011188
2023-03-06 P, Open-market purchase Perrigo Co plcPRGO 190,270, acquired Open Form 4 filing 0001585364-23-000008
2022-06-13 P, Open-market purchase Better Therapeutics, Inc.BTTX 36,183, acquired Open Form 4 filing 0000899243-22-022382
2022-03-29 P, Open-market purchase Better Therapeutics, Inc.BTTX 32,231, acquired Open Form 4 filing 0000899243-22-012959
2021-12-16 P, Open-market purchase Perrigo Co plcPRGO 184,270, acquired Open Form 4 filing 0001585364-21-000122
2021-12-14 P, Open-market purchase Better Therapeutics, Inc.BTTX 98,800, acquired Open Form 4 filing 0000899243-21-048609
2021-03-17 P, Open-market purchase Perrigo Co plcPRGO 103,218, acquired Open Form 4 filing 0001585364-21-000041
2021-03-05 S, Open-market sale ChemoCentryx, Inc.CCXI 2 lines 1,691,468, disposed Open Form 4 filing 0001209191-21-018788
2021-03-04 S, Open-market sale ChemoCentryx, Inc.CCXI 114,980, disposed Open Form 4 filing 0001209191-21-018788
2020-12-10 P, Open-market purchase Tricida, Inc.TCDA 101,700, acquired Open Form 4 filing 0001595585-20-000153
2020-05-12 P, Open-market purchase Tricida, Inc.TCDA 2 lines 84,766, acquired Open Form 4 filing 0001595585-20-000069
2020-05-11 P, Open-market purchase Tricida, Inc.TCDA 2 lines 968,437, acquired Open Form 4 filing 0001595585-20-000069
2020-03-23 S, Open-market sale ChemoCentryx, Inc.CCXI 5 lines 1,101,049, disposed Open Form 4 filing 0001209191-20-021176
2020-03-10 P, Open-market purchase Tricida, Inc.TCDA 147,300, acquired Open Form 4 filing 0001595585-20-000038
2019-11-19 P, Open-market purchase Tricida, Inc.TCDA 32,810, acquired Open Form 4 filing 0001595585-19-000262
2019-11-18 P, Open-market purchase Tricida, Inc.TCDA 653,205, acquired Open Form 4 filing 0001595585-19-000262
2019-08-13 P, Open-market purchase Tricida, Inc.TCDA 2 lines 396,302, acquired Open Form 4 filing 0001595585-19-000170
2019-08-12 P, Open-market purchase Tricida, Inc.TCDA 2 lines 573,568, acquired Open Form 4 filing 0001595585-19-000170
2019-05-30 S, Open-market sale ChemoCentryx, Inc.CCXI 153,806, disposed Open Form 4 filing 0001209191-19-034054
2018-11-13 P, Open-market purchase Tricida, Inc.TCDA 148,600, acquired Open Form 4 filing 0001595585-18-000020
2018-11-12 P, Open-market purchase Perrigo Co plcPRGO 196,058, acquired Open Form 4 filing 0001585364-18-000097
2018-07-02 P, Open-market purchase Tricida, Inc.TCDA 1,140,000, acquired Open Form 4 filing 0001140361-18-031039
2016-12-09 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 2,318, acquired Open Form 4 filing 0001179110-16-033153
2016-12-09 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 2,318, acquired Open Form 4 filing 0001179110-16-032838
2016-12-08 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 12,159, acquired Open Form 4 filing 0001179110-16-033153
2016-12-08 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 12,159, acquired Open Form 4 filing 0001179110-16-032838
2016-11-21 P, Open-market purchase Perrigo Co plcPRGO 221,875, acquired Open Form 4 filing 0001585364-16-000440
2016-05-26 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 4,455, acquired Open Form 4 filing 0001179110-16-025648
2016-05-25 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 10,933, acquired Open Form 4 filing 0001179110-16-025586
2016-05-24 P, Open-market purchase Sunesis Pharmaceuticals IncSNSS 13,881, acquired Open Form 4 filing 0001179110-16-025586
2016-05-13 P, Open-market purchase ChemoCentryx, Inc.CCXI 161,388, acquired Open Form 4 filing 0001209191-16-119901

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
P, Open-market purchase
Open-market purchase
Relationships on this page
O, Officer
Officer
D, Director
Director

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 75
  • Open-market sale 13
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Parker Geoffrey M., insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001491874

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.